Notogen, Inc., a biotechnology company developing regenerative therapeutics for conditions related to disc degeneration, recently announced that it has entered a worldwide research collaboration and license agreement with Boehringer Ingelheim to develop and commercialize a Notogen regenerative therapeutic that has the potential to become a first-in-class, disease modifying treatment for people living with degenerative disc disease (DDD).
Notogen Inc. is a CAAP® company and presented at the OBIO® Investment Summit.